# Role of E5 from HPV16 in the Evasion of the Immune Response

## TL;DR

This review explains how the HPV16 E5 protein helps the virus avoid the immune system and supports its role as a target for new treatments.

## Contribution

The paper integrates molecular and immunological mechanisms of E5 to highlight its potential as a therapeutic target.

## Key findings

- E5 hijacks EGFR, MAPK/ERK, and PI3K/AKT pathways to promote cell survival and proliferation.
- E5 suppresses innate immunity by interfering with IFN-κ, IFN-β, and related signaling pathways.
- E5 disrupts adaptive immunity by impairing MHC-I and MHC-II functions.

## Abstract

Human papillomavirus type 16 (HPV16) persistence relies on early viral mechanisms that synchronize oncogenic signaling with immune evasion, with the E5 oncoprotein serving as a central regulator of the viral cycle and the initiation of cell transformation. This review integrates current evidence on how E5 reconfigures host cell dynamics: first, by hijacking signaling pathways such as EGFR, MAPK/ERK, and PI3K/AKT to drive keratinocyte proliferation and survival; and second, by organizing a multi-step immune evasion strategy. We detail how E5 suppresses innate antiviral responses, specifically by repressing IFN-κ and IFN-β via interference with IRF1, TGF-β/SMAD, STING, and MAVS signaling. Simultaneously, E5 interferes with the adaptive immunity by disrupting MHC-I trafficking and impairing MHC-II maturation. Furthermore, preclinical studies utilizing various vaccine platforms targeting HPV16 E5 have demonstrated the capacity to reduce tumor burden and significantly increase survival rates. By integrating these molecular and immunological checkpoints, we highlight the role of E5 in sustaining viral persistence and underscore its potential as a high-value target for next-generation immunotherapeutic and vaccine-based strategies.